Panacea Venture, CTI Life Sciences and 3B Future Health Fund led a $42m Series A round in Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors in immuno-oncology, with participation from adMare BioInnovations, Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and Seventure Partners. "We are pleased to welcome our new shareholders and I thank them all for their commitment at this decisive stage of our company’s growth. After having delivered a first GPCR drug candidate for immuno-oncology together with Merck KGaA, Domain is now committed to advance its own treatments reviving the immune system to defeat cancer," Pascal Neuville, Domain Therapeutics CEO.